Table 4 Comparison of patients of the G3S cohort 1 (R1E) and IPC cohort 2 (R2E) eligible for the RIOP trial with patients eligible for the TARGIT E study and not eligible for RIOP (TE-RE)

n

499/1411 (36.8%)

304/803

114/592 (19.3%)

154/592 (26%)

 Median

73

74

0.376

74

74

0.27

 Range

70–100

70–101

70–91

70–94

 Median (CI95 %)

10 (10.7–11.4)

13 (13.7–15.4)

<0.0001

12 (11.4–13.1)

16.5 (15.7–18.1)

0.001

 Range

1–20

0,2–35

3–20

3–34

 Ductal

423 (84.8%)

280 (92.4%)

0.001

114 (100%)

154 (100%)

NS

 Lobular

0

0

0

0

 Mixed

0

0

0

0

 Other

76 (15,2%)

23 (7,6)

0

0

 1

268 (53.7%)

63 (20.8%)

<0.0001

1–2

114 (100%)

115 (78.8%)

<0.0001

 2

231 (46.3%)

118 (38.9%)

 3

0

109 (36%)

3

0

31 (21.2%)

 Unknown

0

13 (4.3%)

 pN0

499 (100%)

304 (100%)

NS

pN0

114 (100%)

129 (100%)

NS

 i+

0

≤3

0

0

 mic

0

>3

0

0

 macro

0

unknown

0

0

 +

499 (100%)

211 (70.6%)

<0,0001

114 (100%)

61 (39.9%)

<0.0001

 -

0

88 (29.4%)

92 (60.1%)

 Yes

13 (3.7%)

15 (8.8%)

0.015

2 (7.4%)

7 (9.9%)

0.08

 No

337 (96.3%)

155 (91.2%)

25 (92.6%)

64 (90.1%)

 Yes

0

0

NS

0

0

NS

 No

499 (100%)

159 (100%)

114 (100%)

129 (100%)

 Unknown

 Positive

0

0

NS

0

0

NS

 Negative

499 (100%)

304 (100%)

114 (100%)

146 (100%)

 Yes

0

0

NS

0

0

NS

 No

499 (100%)

304 (100%)

114 (100%)

151 (100%)

 Yes

11 (2.4%)

42 (14.5%)

<0.001

11 (9.6%)

28 (18.2%)

0.036

 No

440 (97.6%)

248 (85.5%)

103 (90.4%)

126 (81.8%)

 Yes

428 (86.7%)

206 (68%)

<0.0001

114 (100%)

61 (39.9%)

<0.0001

 No

69 (13.9%)

97 (32%)

0

92 (60.1%)

 Yes

92 (80.7%)

116 (84.7%)

0.25

 No

22 (19.3%)

21 (15.3%)